The Effectiveness of Local Conservative Therapy after Panretinal Laser Coagulation against the Background of Diabetic Neuropathy

ORIGINAL ARTICLE
Maria N. Ponomareva, Ivan M. Petrov, Evgeniya K. Gribanova

 
International Journal of Biomedicine. 2021;11(3):271-274.
DOI: 10.21103/Article11(3)_OA3
Originally published September 9, 2021

Abstract: 

Background: Panretinal photocoagulation (PRP) (also called scatter laser treatment) remains one of the effective methods of treatment, and it can help to prevent blindness and low vision in diabetic retinopathy (DR). The aim of this study was to investigate the efficacy of local prolonged conservative therapy after PRP and the effect of somatic polymorbidity on visual functions in patients with diabetic neuropathy (DN) at the stage of clinical manifestations based on monitoring the clinical, functional and morphometric parameters of the macular region of the retina.
Methods and Results: The study included 78 patients with type 2 diabetes (T2D) who underwent PRP for DR using a VISULAS® 532s solid-state laser (ZEISS). The patients were divided into two groups depending on the presence or absence of DN. Group 1 (n=60, 120 eyes) included patients with DN (stage of clinical manifestations), Group 2 (n=18, 36 eyes) included patients without DN. All patients underwent standard ophthalmological examination: visometry, tonometry, perimetry, biomicroscopy of the anterior segment of the eye and vitreous body, and fundus ophthalmoscopy. Thickness map of the retina was obtained using the RTVue-100 OCT (Optovue, Fremont, CA) EMM5 scan protocol and the Stratus OCT (Carl Zeiss Meditec, USA) radial scan protocol. After laser treatment, all patients, regardless of the treatment stage, were prescribed topically Broxinac® ( Bromfenac ophthalmic solution 0.09%), 1 drop twice a day for a month. In the presence of macular edema, a carbonic anhydrase inhibitor (Dorzolamide 2% solution) was added to the Broxinac® solution (1 drop twice a day) for up to 1 month after each PRP stage. The dynamics of CVA parameters and the retinal thickness of the macular region were assessed before PRP and 3 months after the complex treatment.
Based on the monitoring of the clinical, functional and morphometric parameters of the macular region of the retina after PRP in T2D patients, we found a local, prolonged, 3-month conservative therapy to be effective, using the instillation of Broxinac® supplemented with Dorzolamide 2% solution in the presence of macular edema. Conversely, there is a negative effect of somatic polymorbidity (stage 3 chronic kidney disease), aspartate aminotransferase >40U/L) on corrected visual acuity (CVA) and morphometric parameters of the macular region of the retina during PRP in T2D patients with DN at the stage of clinical manifestations.

Keywords: 
diabetes mellitus • diabetic neuropathy • panretinal photocoagulation
References: 

1. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. The 9th edition. Diabetes Mellitus. 2019;22(1S1). doi: 10.14341/DM20191S1. [In Russian].
2. Introduction: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2. doi: 10.2337/dc18-Sint01. 
3. Diabetes mellitus: diagnosis, treatment, prevention. Ed. Dedova II, Shestakova MV. Moscow: Medical Information Agency, 2011. [In Russian].
4. Trukhan DI, Lebedev OI. Izmenenie organa zreniia pri somaticheskikh zabolevaniiakh [Change in the organ of vision in somatic diseases]. Ter Arkh. 2015;87(8):132-136. doi: 10.17116/terarkh2015878132-136. [Article in Russian].
5. Kazaykin VN. Diabetic retinopathy: clinical presentation, diagnosis, and treatment. Moscow: Medinform, 2016. [In Russian].
6. Khramilip VN, Demidova IU, Ignatova OY. [Prevalence of diabetic polyneuropathy in newly diagnosed type 2 diabetes mellitus]. Vrach (The Doctor). 2009;5:40-43. [Article in Russian].
7. Al-Zamil MH, Kochetova OV. [Diabetes mellitus and diabetic neuropathy: a historical aspect]. Klinicheskaia Nevrologiia. 2009;3:45-47. [Article in Russian].
8. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia. 2005 Aug;48(8):1637-44. doi: 10.1007/s00125-005-1828-x.
9. Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT; Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014 Dec;121(12):2443-51. doi: 10.1016/j.ophtha.2014.07.019. 
10. Bobykin EV. [Current approaches to the treatment of diabetic macular edema. A literature review]. Fyodorov Journal of Ophthalmic Surgery. 2019;(1):67-76. doi: 10.25276/0235-4160-2019-1-67-76. [Article in Russian].
11. Mozherencov VP, Prokofyeva GL, Usova LA. [Ocular manifestations of diabetes mellitus]. Russian Journal of Clinical Ophthalmology. 2002;1:31. [Article in Russian].
12. Astakhov YuS, Shadrichev FE, Krasavina MI, Grigorieva NN. [Modern approaches to the treatment of diabetic macular edema]. Ophthalmology Journal. 2009;2(4): 59–69. [Article in Russian].

Download Article
Received June 24, 2021.
Accepted August 3, 2021.
©2021 International Medical Research and Development Corporation.